Trends in mental health clinical research: Characterizing the ClinicalTrials.gov registry from 2007-2018.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
    • Abstract:
      While the epidemiologic burden of mental health disorders in the United States has been well described over the past decade, we know relatively little about trends in how these disorders are being studied through clinical research. We examined all US interventional mental health trials submitted to ClinicalTrials.gov between October 1, 2007 and April 30, 2018 to identify trends in trial characteristics, comparisons with non-mental health trials, and trial attributes associated with discontinuation and results reporting. International data were excluded to minimize potential confounding. Over this period, mental health and non-mental health trials grew at similar rates, though Industry and US government-funded trials declined and academic medical center/hospital/other (AMC/Hosp/Oth) funded trials grew faster in mental health research. The proportion of trials with safeguards against bias, including blinding and oversight by data monitoring committees (DMCs), decreased. This occurred during growth in the proportion of trials studying behavioral and non-pharmacological interventions, which often cannot be blinded and do not require DMC oversight. There was concurrent decline in pharmaceutical trials. There was significant growth in trials studying Non-DSM (Diagnostic and Statistical Manual-5) conditions (e.g. suicidality and wellness), as well as substance use, anxiety, and neurocognitive disorders. One in 12 trials was discontinued. Trial discontinuation was associated with industry and AMC/Hosp/Oth funders, pharmaceutical interventions, and lack of DMC oversight. Only 29.9% of completed trials reported results to the registry. Decreased results reporting was associated with behavioral interventions, phase 1 trials, and industry and AMC/Hosp/Oth funders. The main implications of these data are that funding is shifting away from traditional government and industry sources, there is increasing interest in non-pharmacological treatments and Non-DSM conditions, and there are changing norms in trial design characteristics regarding safeguards against bias. These trends can guide researchers and funding bodies when considering the trajectory of future mental health research.
      Competing Interests: The authors have declared that no competing interests exist.
    • References:
      BMJ. 2018 Jun 6;361:k2130. (PMID: 29875212)
      Cerebrum. 2013 Apr 02;2013:5. (PMID: 23720708)
      Acad Psychiatry. 2014 Apr;38(2):145-50. (PMID: 24493358)
      Psychol Addict Behav. 2016 Nov;30(7):764-770. (PMID: 27786511)
      BMJ Open. 2015 Nov 12;5(11):e009758. (PMID: 26563214)
      JAMA. 2016 Dec 27;316(24):2627-2646. (PMID: 28027366)
      BMC Med. 2016 Jul 04;14(1):100. (PMID: 27377062)
      BMJ. 2016 Feb 17;352:i637. (PMID: 26888209)
      BMC Med. 2016 Nov 30;14(1):192. (PMID: 27899150)
      Science. 2010 Jul 30;329(5991):502-4. (PMID: 20671165)
      Nat Rev Neurosci. 2013 Nov;14(11):810-4. (PMID: 24135697)
      Ann Intern Med. 2014 Apr 1;160(7):477-83. (PMID: 24687070)
      Lancet. 2017 Sep 16;390(10100):1260-1344. (PMID: 28919118)
      N Engl J Med. 2015 Mar 12;372(11):1031-9. (PMID: 25760355)
      Shanghai Arch Psychiatry. 2014 Feb;26(1):54-6. (PMID: 25114483)
      BMJ. 2018 May 25;361:k1452. (PMID: 29802130)
      JAMA Psychiatry. 2014 Jun;71(6):706-15. (PMID: 24789675)
      Acad Psychiatry. 2016 Dec;40(6):869-873. (PMID: 26758737)
      N Engl J Med. 2017 Jan 26;376(4):383-391. (PMID: 28121511)
      Nat Rev Drug Discov. 2012 Aug;11(8):583-4. (PMID: 22850770)
      JAMA Oncol. 2018 Aug 1;4(8):1073-1079. (PMID: 29799987)
      Stud Health Technol Inform. 2017;245:280-284. (PMID: 29295099)
      Can J Surg. 2010 Oct;53(5):345-8. (PMID: 20858381)
      JAMA. 2012 May 2;307(17):1838-47. (PMID: 22550198)
      JAMA. 2015 Dec 15;314(23):2566-7. (PMID: 26670975)
      N Engl J Med. 2019 Nov 14;381(20):1966-1974. (PMID: 31722160)
      Pediatrics. 2012 Nov;130(5):e1269-77. (PMID: 23027172)
      Nature. 2017 Jun 13;546(7658):339. (PMID: 28617481)
      Psychiatry Res. 2019 Nov;281:112552. (PMID: 31627072)
      PLoS One. 2015 Aug 19;10(8):e0133718. (PMID: 26287998)
      JAMA Intern Med. 2017 Feb 1;177(2):274-275. (PMID: 27942726)
      N Engl J Med. 2016 Nov 17;375(20):1998-2004. (PMID: 27635471)
      PLoS One. 2012;7(3):e33677. (PMID: 22438982)
      J Clin Psychiatry. 2012 Jul;73(7):e906-12. (PMID: 22901361)
      BMJ. 2001 Mar 10;322(7286):603-5. (PMID: 11238162)
      Nat Rev Drug Discov. 2015 Dec;14(12):815-6. (PMID: 26585536)
    • Publication Date:
      Date Created: 20200606 Date Completed: 20200820 Latest Revision: 20200820
    • Publication Date:
      20240104
    • Accession Number:
      PMC7274444
    • Accession Number:
      10.1371/journal.pone.0233996
    • Accession Number:
      32502181